Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer

摘要: Abstract Background The occurrence of colorectal cancer in individuals with potentially reproductive age has increased. Oxaliplatin is a cornerstone treatment the adjuvant setting for stage III and high-risk II patients up to 70 years age. aim this study was investigate sex hormones sperm function after oxaliplatin-based chemotherapy clarify risk hypogonadism infertility. Methods Through 2006-2013 20 males (aged ≤55 younger) 16 females ≤40 were included. All had undergone radical surgery due cancer, planned oxaliplatin combination 5-fluorouracil. Measurement LH, FSH, testosterone, SHBG analysis done males. FSH estradiol measured females. Measurements surgery, cessation cytostatic at follow-up 1-5 end treatment. Results testosterone levels increased males, but restored follow-up. No went from normal gonadal hypogonadism. There tendency towards decrease concentration, (p = 0.,063). When comparing concentration rapid progressive motility before follow-up, there no differences, we observed that turned overtly infertile by distinct altering could be Conclusions From results study, seems incur transient recovery, some not pronounced increase infertility low moderate, general recommendation appropriate fertility conserving measures shall should changed. Legal entity responsible authors. Funding Has received any funding. Disclosure P. Osterlund: Honoraria (self): Amgen; Bayer; Celgene; Eli Lilly; Merck; Nordic Drugs; Roche; Sanofi; Servier; Travel / Accommodation Expenses: Pierre Fabre; AstraZeneca; AbbVie. E. Hofsli: Amgen. H. Sorbye: Novartis; Ipsen; Pfizer; Keocyt; Shire; Drugs. other authors have declared conflicts interest.